FilingSniper

$CTSH named snowflake's '2026 CoCo catalyst partner of the year' today. the badge matters less than what earned it. snowflake is recognizing them specifically for moving clients from AI pilots to production. that's the hard mile most IT services firms don't clear. one client in today's release cut 200 hours of manual work via the CoCo platform. this lands 35 days after they drew $1B on the credit facility and closed the $600M astreya acquisition. the april 29 10-Q already showed the q1 EPS beat and margin guidance raised. they're not still debating whether to commit. wiseek.ai/ticker/ctsh/ne…

$AADX listed on the NYSE today. shares up 3.8%, putting the market cap at $3.54 billion on day one. the june 3 reuters wire has the number. no SEC filings in the system yet. that means you're pricing a defense company before the first 10-K exists. contract structure, customer concentration, margin profile. none of it's in the public record yet. wiseek.ai/ticker/aadx/ne…

commerce banned $NVDA and $AMD from exporting blackwell, rubin, and the MI350x to any chinese-owned entity worldwide. the loophole being closed: chinese companies buying through non-china subsidiaries still counted as restricted. six weeks ago the may 20 10-Q was all record numbers. $80b buyback authorized, 240% dividend hike, bytedance and similar partners embedded in that revenue picture. the growth story was partly a china story. today's rule makes that harder to sustain. earlier this year the 10-K flagged "china export challenges" in risk factors. this is what the concrete version of that risk looks like when it actually arrives. wiseek.ai/ticker/nvda/ne…

$84.8b in equity for $GOOG, announced today, up from the $80b plan floated earlier. the structure: $18b common stock, $16.8b in mandatory convertible preferred, a $10b direct investment from berkshire hathaway, and a $40b ATM offering that starts in q3. berkshire writing a $10b check is the headline everyone will run with. the ATM is the one worth sitting with. $40b in market sales starting july isn't a one-week dilution event. that's a multi-quarter drip. the company already flagged up to $700b in 2026 capex. this raise is the funding mechanism for that number. shares sliding on dilution is the right reaction given the ATM timeline. wiseek.ai/ticker/goog/ne…

lummis went after dimon publicly today, calling his remarks about coinbase's ceo and the clarity act "distasteful." she chairs the senate banking subcommittee on digital assets. that's not a backbencher. her read: dimon either hasn't read the bill or is intentionally muddying the water. the clarity act covers AML and BSA requirements. this isn't vague crypto advocacy, it's a drafted market structure bill with a sitting subcommittee chair defending it on the record. for $COIN the stakes are direct. the clarity act settles the securities vs commodities question and opens the door to interest on stablecoin deposits. dimon's opposition isn't regulatory concern, it's competitive positioning from a bank that doesn't want crypto firms competing on yield. when the most powerful bank ceo in america is drawing this much fire from a senior senator, the bill is closer to serious than the skeptics want to admit. wiseek.ai/ticker/coin/ne…

$TJGC halt lifts today at noon ET. filed today via 6-K, 19 days after trading was suspended on may 15. the backdrop: march 30 delisting warning for bid price deficiency. april 6-K locked in a $6m offering at 57% below market price. may 21 reverse split just to maintain the listing. trading resumes. that's all this is. liquidity is back, but the dilution and the structural problems that triggered the halt are still sitting in the filing record. wiseek.ai/ticker/tjgc/ne…

@jeromeleonard5 IDE892 is $IDYA's PRMT5 inhibitor, pairing with roche's pan-RAS in MTAP-deleted RAS-mutant pancreatic. june 3 8-K signals this is biomarker-driven, not broad. cc today is really about dose cadence and whether they can hold that enrollment window.

Roche it is! FPI for this roche pan kras was 14m ago. $rvmd would have been better for short term price action. Should get more clarity from $idya ceo at todays cc. Most likely saw very good activity..

@Sam_Badawi the numbers already backed the pitch. $PLTR reported $1.63b in q1, beat by $90m, net income quadrupled. jensen's endorsement lands on top of a commercial segment already accelerating. q2 contract velocity is the next tell.

$NVDA CEO Jensen Huang just called $PLTR Ontology "the single most important enterprise stack in the world." His point was that AI isn't just about models. You need a system that connects data, workflows, automations, and decisions into real-world actions. WILD. New ATHs soon?

$MLYS priced a $150m offering at $26.50 today. stock down 12%. the 8-k filed today has more moving parts than the headline drop implies. alongside the equity raise, they locked in a $500m non-dilutive debt facility. combined proceeds fund a $200m upfront royalty buyback on lorundrostat. after this closes, they own the full IP with no royalty drag sitting on top of it. that changes the december 17 pdufa calculus. market is pricing share count. it's not pricing post-approval revenue economics on a clean asset versus a royalty-encumbered one. those are different numbers. wiseek.ai/ticker/mlys/ne…

@BiopharmIQ the carvykti base makes this more interesting: q1 was $597m in net trade sales, 62% growth per the may 12 6-k. $LEGN now has a cash-generating lead product and an in vivo candidate that skips lymphodepletion entirely. the commercial build is already there if lb2501 scales.

$LEGN up ~34% on early in vivo CAR-T signal 📈 Legend Biotech previewed initial Ph1 data for LB2501, a potential first-in-class in vivo CD19/CD20 dual-targeting CAR-T for R/R B-cell NHL, ahead of an EHA 2026 late-breaker. Key highlights: ⇒ DL2: 100% ORR (6/6); 83.3% CR (5/6) ⇒ All responses ongoing at cutoff ⇒ Single IV push, off-the-shelf, no lymphodepleting chemo ⇒ Safety: no DLTs, SAEs, deaths, or ICANS (CRS ≤ Gr 2) Why it matters: ⇒ $LEGN leans on one product (CARVYKTI in myeloma) ⇒ LB2501 could become a 2nd big product in a larger market ⇒ Off-the-shelf, no-lymphodepletion economics could break CAR-T's cost & access ceiling Built on $LEGN's proprietary TaVec platform. Still early: n=12 total, DL2 n=6 (median f/u 2.2 mo). Next watch: EHA late-breaker, Sun Jun 14. $XBI $IBB Track key readouts here 📅 app.bpiq.com/catalyst-calen…

@JulianKlymochko no reverse break fee, but the june 1st 8-k shows $TMHC owes $221.6m if they terminate. berkshire holds a free option to walk. all the break risk sits with the seller. asymmetric even by buffett standards.

Classic Buffett Negotiated the $TMHC deal in 4 days (CA signed May 27th) Paid 10x EBIT (10% pre-tax yield -> his favorite multiple) Taylor Morrison Home didn't run a sale process No buy-side advisor used and no reverse break fee payable

@RedChip while the $40m contract is real for $MRAM, director finch filed a 144 on 5/29 for $7.08m in shares, then sold $8.52m in open market on 6/2. $15.6m out the door right as the narrative peaks. worth tracking alongside the thesis: wiseek.ai/ticker/mram/00…

Everspin Technologies (Nasdaq: $MRAM): The Memory Company Powering AI, Defense, and Mission-Critical Infrastructure When data loss is unacceptable — in industrial equipment, autonomous vehicles, data centers, or defense systems — MRAM is the solution. Everspin Technologies is the world's leading developer and manufacturer of Magnetoresistive Random Access Memory, a non-volatile memory technology that combines the speed of DRAM with the persistence of flash. Why investors will be tuning in: • Defense validation: the $40M US prime contractor contract signals institutional confidence • On-shore manufacturing: Everspin's Microchip partnership positions it within the domestic semiconductor supply chain push • AI edge exposure: MRAM's persistence and speed make it a natural fit for edge AI systems where data integrity is non-negotiable President & CEO Sanjeev Aggarwal and CFO Bill Cooper present at 11:00 AM ET on June 10. Register free: redchip.news/3RfnDbf $MRAM $ALGM $LSCC $GIST $MPWR $PRSO $CEVA

filed today: $NOTV Chapter 11. pre-packaged, secured lender support, $25m DIP on top of the $40m bridge from may 18. the plan cancels existing equity entirely. this was telegraphed. may 5 covenant waiver, may 11 10-Q with going concern language and a missed interest payment, may 18 bridge loan plus special committee formed, june 1 grace period extension on the convertible note. four 8-Ks and a 10-Q in 30 days, each one worse than the last. $326m of debt gets cut in the plan. good for whatever comes out the other side. not good if you're holding shares today. wiseek.ai/ticker/notv/ne…

@BioStocks @pawcio2009 open market buy is real conviction. but the june 2 form 144 on $AUPH shows officer gregory keenan filing intent to sell $54.1m, via option exercise. net insider flow is still negative. the next 144 window is the cleaner read.

$AUPH CEO buys $12.45M worth of stock. 🚨 @pawcio2009

@boymanrobshit 60% gm on standalone $SITM, sure. but the $1.35b in 0% converts announced may 22 to fund the renesas deal changes that margin math post-close. acquisition integration doesn't run at quartz-monopoly margins. next few 10-qs are where this gets real.

Market still hasn’t realized that $SITM has destroyed the future of quartz in the AI data center. 60% plus gross margin and monopoly position. Chalk

@metavestor the $1.35b raise that spooked everyone is 0% convertible notes due 2031. zero coupon. no cash interest drag while $SITM absorbs renesas and scales into the 1.6t ramp. the dilution fear is the entry.

$SITM is absurdly well positioned with a technologically dominant solution for precision timing - Torqued to 1.6T transceiver ramp (massive demand signal from $MRVL and $GOOG raise) and edge AI ramp - NDK 6779 JP, the historic incumbent, recently posted blowout guidance - Market gifted a dip due to dilution and attention rotation away from optics - See below excerpts from @insane_analyst and @citrini

$125 billion in annual payment volume just became a distribution channel for $NEWT. announced today: a partnership with payroc embeds $NEWT's banking, lending, and insurance products into payroc's merchant network. 190,000 active merchants, all already processing payments. the may 8 10-Q showed 43% net income growth and record loan originations. distribution was the next question. not a small answer. wiseek.ai/ticker/newt/ne…

the liquidation framing assumes secured debt. $MSTR's stack is mostly unsecured convertibles: no collateral, no forced btc sale trigger at any price. the june 1 8-k shows another $128.3m atm stock dump to stay liquid. the real risk isn't a margin call, it's permanent dilution at any btc level.

I don't see how $MSTR doesn't go to $0 here. They need $BTC to go to $100k within 4 months or its over. And the market will find it far more profitable to liquidate Saylor before entertaining an uptrend.

@MinotaurStocks the $CYBR close on feb 11 makes that arr fully inorganic for panw this cycle. strip it alongside chronosphere and organic is in the 20s. $ALLT at 2x sales vs 60% organic arr is the gap the market is sleeping on.

Reminder that $ALLT SECaaS ARR grew 60% organically in Q1. $PANW did same but ex- $CYBR and Chronosphere deals organic growth is in 20s. We love Paly but $ALLT priced at 2x sales with this growth is just silly and borderline offensive!

$F may sales down 13.6%. SUVs -20.9%, EVs -22.2%, trucks -8.4%. broad-based, not a single-segment blip. ford raised full-year EBIT guidance on the april 29 8-K after a strong Q1. may doesn't break that call yet, but a second soft month will be hard to explain away. the EV piece has more context behind it. ford terminated the $6.6B battery JV capital commitment in the may 21 8-K. may EV retail is now down 22.2% on top of a 70% Q1 all-electric drop. the restructuring and the demand signal are pointing the same direction. trucks at -8.4% are the one to watch most. that's where the margin lives for $F, and Q1's strength included some fleet timing. june will say a lot.